Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 5, 2016, Pages 1028-1036

  Mak, Kimberley S ^a,b   Smith, Angela B ^c   Eidelman, Alec ^d   Clayman, Rebecca ^d   Niemierko, Andrzej ^d   Cheng, Jed Sian ^d   Matthews, Jonathan ^c   Drumm, Michael R ^d   Nielsen, Matthew E ^c   Feldman, Adam S ^d   Lee, Richard J ^d   Zietman, Anthony L ^d   Chen, Ronald C ^c   Shipley, William U ^d   Milowsky, Matthew I ^c   Efstathiou, Jason A ^d  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DIAGNOSIS; DISEASES; MUSCLE; PATIENT MONITORING; SURVEYS;

EXPANDED PROSTATE CANCER INDEX COMPOSITES; HEALTH-RELATED QUALITY OF LIVES; INFORMED DECISION; METHODS AND MATERIALS; MULTIVARIABLE ANALYSIS; PERFORMANCE STATUS; PROPENSITY SCORE MATCHING; RADICAL CYSTECTOMY;

PATIENT TREATMENT;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVOR; CANCER TREATMENT AND PERCEPTION SCALE; COGNITION; COMORBIDITY; CONFERENCE PAPER; CROSS-SECTIONAL STUDY; CYSTECTOMY; DECISION MAKING; EMOTION; EORTC QUALITY OF LIFE CORE QUESTIONNAIRE; EUROQOL QUESTIONNAIRE; EXPANDED PROSTATE CANCER INDEX COMPOSITE BOWEL SCALE; FEMALE; FOLLOW UP; HUMAN; ILEAL CONDUIT; IMPACT OF CANCER VERSION 2 SCALE; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROPENSITY SCORE; QUALITY OF LIFE; SALVAGE THERAPY; SEXUAL FUNCTION; SOCIAL INTERACTION; TOBACCO; URINARY TRACT DISEASE ASSESSMENT; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; INTESTINAL DISEASES; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUSCLE; NONPARAMETRIC TEST; PATHOLOGY; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; RADIOTHERAPY DOSAGE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SURVIVOR; TIME FACTOR; TUMOR INVASION; URINARY BLADDER NEOPLASMS; URINATION DISORDERS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; CROSS-SECTIONAL STUDIES; CYSTECTOMY; FEMALE; HUMANS; INTESTINAL DISEASES; MALE; MULTIVARIATE ANALYSIS; MUSCLES; NEOPLASM INVASIVENESS; ORGAN SPARING TREATMENTS; PROPENSITY SCORE; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; STATISTICS, NONPARAMETRIC; SURVEYS AND QUESTIONNAIRES; SURVIVORS; TIME FACTORS; URINARY BLADDER NEOPLASMS; URINATION DISORDERS;

EID: 84992372755     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.08.023     Document Type: Conference Paper

References (30)

1. 1 Basch, E., Abernethy, A.P., Mullins, C.D., et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 30 (2012), 4249–4255.
2. 2 Porter, M.P., Penson, D.F., Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: A systematic review and critical analysis of the literature. J Urol 173 (2005), 1318–1322.
3. 3 Botteman, M.F., Pashos, C.L., Hauser, R.S., et al. Quality of life aspects of bladder cancer: A review of the literature. Qual Life Res 12 (2003), 675–688.
4. 4 Huddart, R.A., Hall, E., Lewis, R., et al. Life and death of SPARE (selective bladder preservation against radical excision): Reflections on why the SPARE trial closed. BJU Int 106 (2010), 753–755.
5. 5 Mak, R.H., Hunt, D., Shipley, W.U., et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32 (2014), 3801–3809.
6. 6 Efstathiou, J.A., Spiegel, D.Y., Shipley, W.U., et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience. Eur Urol 61 (2012), 705–711.
7. 7 Ploussard, G., Daneshmand, S., Efstathiou, J.A., et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: A systematic review. Eur Urol 66 (2014), 120–137.
8. 8 EuroQol Group. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy 16 (1990), 199–208.
9. 9 Aaronson, N.K., Ahmedzai, S., Bergman, B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
10. 10 Bladder Cancer: EORTC QLQ-NMIBC24, EORTC QLQ-BLM30. Internet, available from http://groups.eortc.be/qol/bladder-cancer-eortc-qlq-nmibc24-eortc-qlq-blm30, Accessed September 15 2016.
11. 11 Wei, J.T., Dunn, R.L., Litwin, M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000), 899–905.
12. 12 Clark, J.A., Bokhour, B.G., Inui, T.S., et al. Measuring patients’ perceptions of the outcomes of treatment for early prostate cancer. Med Care 41 (2003), 923–936.
13. 13 Crespi, C.M., Ganz, P.A., Petersen, L., et al. Refinement and psychometric evaluation of the impact of cancer scale. J Natl Cancer Inst 100 (2008), 1530–1541.
14. 14 Cocks, K., King, M.T., Velikova, G., et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29 (2011), 89–96.
15. 15 Pickard, A.S., Neary, M.P., Cella, D., Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes, 5, 2007, 70.
16. 16 Piccirillo, J.F., Tierney, R.M., Costas, I., et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291 (2004), 2441–2447.
17. 17 Skolarus, T.A., Dunn, R.L., Sanda, M.G., et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology 85 (2015), 101–105.
18. 18 Shabsigh, A., Korets, R., Vora, K.C., et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 55 (2009), 164–174.
19. 19 Efstathiou, J.A., Bae, K., Shipley, W.U., et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27 (2009), 4055–4061.
20. 20 Bruner, D.W., Movsas, B., Basch, E., Capturing the patient perspective: Patient-reported outcomes as clinical trial endpoints. Am Soc Clin Oncol Educ Book, 2012, 139–144.
21. 21 Lagrange, J.L., Bascoul-Mollevi, C., Geoffrois, L., et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: Results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys 79 (2011), 172–178.
22. 22 Caffo, O., Fellin, G., Graffer, U., et al. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma: A survey by a self-administered questionnaire. Cancer 78 (1996), 1089–1097.
23. 23 Henningsohn, L., Wijkstrom, H., Dickman, P.W., et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 62 (2002), 215–225.
24. 24 Weiss, C., Wolze, C., Engehausen, D.G., et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: An alternative to intravesical therapy or early cystectomy?. J Clin Oncol 24 (2006), 2318–2324.
25. 25 Singer, S., Ziegler, C., Schwalenberg, T., et al. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer 21 (2013), 1383–1393.
26. 26 Feuerstein, M.A., Goenka, A., Quality of life outcomes for bladder cancer patients undergoing bladder preservation with radiotherapy. Curr Urol Rep, 16, 2015, 547.
27. 27 Zietman, A.L., Sacco, D., Skowronski, U., et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol 170 (2003), 1772–1776.
28. 28 Kramer, M.W., von Klot, C.A., Kabbani, M., et al. Long-term bowel disorders following radial cystectomy: An underestimated issue?. World J Urol 33 (2015), 1373–1380.
29. 29 Wilson, I.B., Cleary, P.D., Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA 273 (1995), 59–65.
30. 30 Ali, A.S., Hayes, M.C., Birch, B., et al. Health related quality of life (HRQoL) after cystectomy: Comparison between orthotopic neobladder and ileal conduit diversion. Eur J Surg Oncol 41 (2015), 295–299.